Michael Cloonan sold $624k of SION
President & CEO at Sionna Therapeutics, Inc.. 25,000 shares at an average of $24.97, traded Aug 26, 2025, filed Aug 28, 2025.
Score components
- +25RoleCEO
- +20Trade size$624k at market
- 0Share of holdings soldSold 4.4% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0002036042-25-000051, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 26, 2025 | MOption exercise Common Stock10b5-1 | +17,574 | $6.11 | $107k | 564,917 | Aug 28, 2025 |
| Aug 26, 2025 | SOpen-market sale Common Stock10b5-1 | -17,574 | $24.96 | $439k | 547,343 | Aug 28, 2025 |
| Aug 27, 2025 | MOption exercise Common Stock10b5-1 | +7,426 | $6.11 | $45k | 554,769 | Aug 28, 2025 |
| Aug 27, 2025 | SOpen-market sale Common Stock10b5-1 | -7,426 | $25.01 | $186k | 547,343 | Aug 28, 2025 |
| Aug 26, 2025 | MOption exercise Non-Qualified Stock Option (right to buy)derivative10b5-1 | -17,574 | $0.00 | $0 | 210,568 | Aug 28, 2025 |
| Aug 27, 2025 | MOption exercise Non-Qualified Stock Option (right to buy)derivative10b5-1 | -7,426 | $0.00 | $0 | 203,142 | Aug 28, 2025 |
Related signals
Other insiders at Sionna Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 50Moderate | SIONsell Sionna Therapeutics, Inc. | Ra Capital Management, L.p. director, owner | $22M 3,448,811 shares | -50% | |
| 28Weak | Sionna Therapeutics, Inc. | Michael Cloonan President & CEO | $3.6M 99,800 shares | -18% | |
| 28Weak | Sionna Therapeutics, Inc. | Bruce Booth director | $3.0M 88,878 shares | -4% | |
| 33Weak | Sionna Therapeutics, Inc. | Bruce Booth director | $9.3M 286,369 shares | -11% | |
| 20Weak | Sionna Therapeutics, Inc. | Michael Cloonan President & CEO | $788k 25,200 shares | -4% | |
| 28Weak | Sionna Therapeutics, Inc. | Bruce Booth director | $5.9M 194,932 shares | -7% | |
| 28Weak | Sionna Therapeutics, Inc. | Bruce Booth director | $1.5M 49,546 shares | -2% | |
| 28Weak | Sionna Therapeutics, Inc. | Bruce Booth director | $2.4M 78,693 shares | -3% | |
| 19Weak | Sionna Therapeutics, Inc. | Michael Cloonan President & CEO | $728k 25,000 shares | -4% | |
| 28Weak | Sionna Therapeutics, Inc. | Jennifer Fitzpatrick Chief Legal Officer | $237k 10,250 shares | -100% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.